Neurocrine Biosciences (NBIX) Convertible Debt (2017 - 2023)

Neurocrine Biosciences' Convertible Debt history runs 7 years deep, the most recent figure standing at $169.5 million for Q1 2023.

• Quarterly Convertible Debt fell 55.12% year-over-year to $169.5 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $169.5 million (down 55.12% YoY) and the FY2021 annual result came in at $335.1 million, up 5.41% from the prior year.
• Convertible Debt was $169.5 million for Q1 2023 at Neurocrine Biosciences, roughly flat from $169.0 million in the prior quarter.
• Across five years, Convertible Debt topped out at $414.1 million in Q1 2020 and bottomed at $169.0 million in Q2 2022.
• A 5-year average of $329.8 million and a median of $332.9 million in 2021 frame the typical range for Convertible Debt.
• Annual changes were most pronounced in 2022 — Convertible Debt grew 17.3% — and 2023, when it tumbled 55.12%.
• Neurocrine Biosciences' Convertible Debt stood at $403.6 million in 2019, then decreased by 21.23% to $317.9 million in 2020, then advanced by 5.41% to $335.1 million in 2021, then plunged by 49.57% to $169.0 million in 2022, then climbed by 0.3% to $169.5 million in 2023.
• Business Quant data shows NBIX's Convertible Debt at $169.5 million in Q1 2023, $169.0 million in Q2 2022, and $377.7 million in Q1 2022.